On Nov 07, major Wall Street analysts update their ratings for $Jazz Pharmaceuticals (JAZZ.US)$, with price targets ranging from $140 to $207.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $140.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and adjusts the target price from $172 to $182.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $200 to $190.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $200 to $195.
Needham analyst Ami Fadia maintains with a buy rating, and adjusts the target price from $205 to $207.
Furthermore, according to the comprehensive report, the opinions of $Jazz Pharmaceuticals (JAZZ.US)$'s main analysts recently are as follows:
Jazz Pharmaceuticals reported third-quarter revenue in line with expectations and a significant beat on non-GAAP net income, despite facing temporary challenges affecting the Rylaze brand. The overall assessment of the third-quarter results is positive. The company is perceived to be trading at very low multiples, yet is projected to deliver mid-single digit revenue growth and high-single digit earnings growth on an annual compound basis.
Jazz Pharmaceuticals' Q3 revenue surpassed expectations, primarily due to robust performance from its main growth contributors Xywav and Epidiolex. However, Rylaze experienced a temporary setback due to changes in the treatment protocol.
Jazz Pharmaceuticals' total Q3 revenue surpassed expectations, bolstered by strong performances from products including Xywav, Epidiolex, Defitelio, and Zepzelca.
Here are the latest investment ratings and price targets for $Jazz Pharmaceuticals (JAZZ.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
